Highlights

  • Neurizon Therapeutics updates its maximum proposed Options issue to 210,294,116.
  • The change accommodates potential SPP subscriptions above the AUD 2 million target.
  • The revised maximum assumes up to AUD 10 million in SPP proceeds.
  • One option per subscribed share remains subject to Shareholder approval.

Neurizon Therapeutics Limited (ASX: NUZ), a clinical-stage developer of treatments for neurological conditions, has updated its proposed securities issue to allow for a maximum of 210,294,116 options. The 16 November 2026 Appendix 3B revision reflects the possibility that its Share Purchase Plan, initially targeting AUD 2 million, could accept oversubscriptions. The maximum calculation assumes an SPP raising up to AUD 10 million; it does not confirm that such funds have been received.

What Changed in the Appendix 3B

The regulatory update revises the maximum number of options in an earlier proposed-issue announcement dated 2 November 2026. Neurizon says it reserved the right to accept subscriptions above the SPP target and adjusted the cap to avoid understating the potential issue size in the formal notification.

The distinction between a maximum and an actual allocation is important. The published number represents an upper limit used for the proposal; the final number will depend on subscriptions, the applicable terms and the completion of required approvals. The announcement does not establish a completed Capital raising.

One-for-One Options and Conditional Approval

Participants in the Placement and SPP are intended to be offered one new option for each new share issued or subscribed for, for no separate consideration. The rights attached to these options are conditional on a shareholder vote. The filing identifies 17 December 2026 as the estimated approval date and 22 December as the proposed securities-issue date.

Those are scheduled steps, not completed events. The terms also specify an 18-month option life from issue. A proposed application for Quotation is subject to the relevant ASX requirements, including assessment of the securities’ terms and eligibility.

Why the Revised Limit Matters

A share purchase plan can increase the number of shares issued if the company accepts permitted oversubscriptions. Because Neurizon’s proposal links one option to each new share allotted to eligible participants, a larger SPP would also increase the number of attaching options. The update therefore affects the potential scale of future securities outstanding.

Options are rights that may be exercised under specified terms, not existing ordinary shares on the date of this announcement. Their existence creates possible future issuance and dilution if exercised. Any eventual cash receipts from exercise depend on option holders’ decisions and the option conditions; they are not assured funding today.

Financing Context for a Clinical-Stage Company

Neurizon’s activities involve therapeutic development, where research, regulatory and clinical progress can require funding before a product generates commercial sales. The November notice concerns the mechanics of financing rather than a new clinical efficacy result. It should not be interpreted as confirmation of a trial outcome, regulatory approval or development milestone.

The next disclosed checkpoints are the shareholder decision, the final amount subscribed and the number of options actually issued. Those outcomes will clarify the Capital Structure resulting from the proposal. Any assessment of clinical progress requires separate company disclosures.

Key Insights

The maximum proposed option issue has risen to 210,294,116 to accommodate an assumed AUD 10 million SPP scenario, compared with the AUD 2 million initial target. Neither the maximum subscription amount nor the options issue is final; shareholder approval and completion of the transaction remain outstanding.